CrisprBits Partners With Molbio Diagnostics to Launch CRISPR-Based POC Tests     

The primary objective of this collaboration is to provide cost-effective, innovative, and accurate diagnostic testing. This will increase market opportunities and revolutionise point-of-care diagnostics.'¯  '¯ 

CrisprBits, a biotech start-up, has partnered with Molbio Diagnostics, a point-of-care diagnostics solution to introduce CRISPR into point-of-care (POC) assays and enhance POC diagnostics. 

The partnership marks a significant step ahead in the development of easily accessible, affordable, and reliable diagnostic testing on the frontline. 

CrisprBits has created a platform for developing POC tests that are quick, accurate, and cost-effective for a variety of diseases and health issues. This platform has been developed by utilising a specificity of RNA guide-based target identification of nucleic acid and the existence of both cis & trans-cleavage properties of particular Cas enzymes.'¯ 

CrisprBits will lead in developing its platform, PathCrisp, for testing point-of-care procedures. Molbio Diagnostics, on the other hand, will simultaneously use its extensive manufacturing capacity and recognised sales and marketing network to sell and distribute the developed POC tests worldwide. 

'œBy teaming up with Molbio Diagnostics, we are combining our innovations in instrument-light CRISPR POCTs to develop and distribute a new generation of tests that are pervasive and will enable early detection and timely treatment," said Dr. Vijay Chandru, chief scientific officer and cofounder, CrisprBits. 

The collaboration will be building POCTs to quickly and precisely detect numerous infections and genetic markers on the site. There are several locations where the tests will be made available, including clinics, hospitals, and communities with few resources. However, it is essential to have access to accurate diagnostic equipment.  

Dr. Chandrashekar Nair, chief technical officer, Molbio Diagnostics, said, 'œWe are very excited about this partnership with CrisprBits.  This collaboration aligns perfectly with our overarching mission to provide reliable and accessible point-of-care diagnostic solutions that empower healthcare professionals globally."  

This collaborative partnership intends to accelerate the development, production, and delivery of these game changing POC diagnostics to healthcare facilities and communities all around the world. 

'œBy partnering with Molbio diagnostics we strive to bring to these tests that impact real-time decision-making that leads to enhanced patient outcomes and more effective public health management,' said Sunil Arora, cofounder and CEO, CrisprBits. 

Molbio Diagnostics is the first unicorn in the Indian medical technology market that caters to medical professionals worldwide. They are using Truelab's real-time quantitative micro-PCR system comprising Truenat technology that shows instant PCR testing in all labs. 

CrisprBits, on the other hand, is one of the first companies in India that uses CRISPR, a gene-editing technology. It creates top-notch, affordable life sciences solutions for all Indians. A group of entrepreneurs and scientists with extensive backgrounds in the business and academic worlds formed the company. The company has expertise in creating clinical research, precision medicine, and diagnostics solutions employed by India's biotech companies, pharmaceutical corporations, and clinicians worldwide.